The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...

Since October 2020 – when the Health Sciences Authority (HSA) first authorized sale of an esketamine nasal spray ... to give numbers for Singapore, but Spravato is available at about 2,800 ...

Since October 2020 – when the Health Sciences Authority (HSA) first authorised sale of an esketamine nasal spray ... the ketamine nasal spray Spravato is now a mainstream prescription for ...

The Institute for Clinical and Economic Review (ICER) has published its final report on Spravato (esketamine) and says the drug would need to be between 25% and 52% cheaper to meet its value ...

SPRAVATO® (Esketamine): SPRAVATO® is an innovative treatment for treatment-resistant depression or depression with suicidal thoughts or actions. Administered under medical supervision ...

Yesterday, the drugmaker added to the evidence behind Spravato – an intranasal formulation of esketamine – with the release of top-line data from a head-to-head study with a long-acting ...

SPRAVATO® (Esketamine): SPRAVATO® is an innovative treatment for treatment-resistant depression or depression with suicidal thoughts or actions. Administered under medical supervision, this ...